Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , and Alvotech today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDItm (ustekinumab-aekn) ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) ...

The U.S. FDA has approved SELARSDI (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...

Biocon Biologics Ltd., today announced the Company has secured multiple market access agreements for Yesintek™ ...

A large UK Biobank study found that higher consumption of ultra-processed foods (UPFs) is associated with an increased risk ...

The dosing interval for ixekizumab may be extended in some patients with plaque psoriasis, and switching between biologics may also be considered.

THE MANAGEMENT of plaque psoriasis has evolved significantly over the past two decades, with biologic treatments becoming ...

A real-world study finds elderly psoriasis patients treated with IL-17 and IL-23 inhibitors achieve comparable long-term ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and insights that, taken together, suggest treatment strategies that offer the ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Patients with generalized pustular psoriasis (GPP) experience frequent flares, and treatment alterations of off-label agents are frequently observed.